Author

Cheng Liu

Institution: Eureka Therapeutics (United States)

Observed institution: Eureka Therapeutics (United States)

ORCID: 0000-0002-7419-8529

Observed ORCID: 0000-0002-7419-8529

OpenAlex ID: A5042679881

A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma

2022 · Pengcheng He, Haibo Liu, et al. · Journal of Cancer Research and Clinical Oncology · 23

A Bi-Specific T Cell Engaging Monoclonal Antibody (mAb) Derived From a TCR-Like Mab Specific For WT1/HLA-A0201 (ESK-BiTE) Shows a Potent Activity Against Human AML and Ph+ ALL In Mouse Models

2013 · Dmitry Pankov, Tao Dao, et al. · Blood · 5

High-avidity cathepsin-G–specific CAR T cells for the treatment of acute myeloid leukemia

2026 · Tara Walhart, Marta Biondi, et al. · Blood · 1

Phase I Study of CD19-ARTEMIS® T Cells (EB103) in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma

2026 · Naseem Esteghamat, Pei Wang, et al. · Transplantation and Cellular Therapy

Works count: 4

Citation count: 29

H-index: 2

I10-index: 1